Celgene Corporation (NASDAQ:CELG) Director Sells $1,230,712.50 in Stock

Celgene Corporation (NASDAQ:CELG) Director Michael D. Casey sold 9,250 shares of the business’s stock in a transaction on Wednesday, June 21st. The shares were sold at an average price of $133.05, for a total transaction of $1,230,712.50. Following the transaction, the director now directly owns 9,250 shares of the company’s stock, valued at approximately $1,230,712.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Michael D. Casey also recently made the following trade(s):

  • On Monday, June 19th, Michael D. Casey sold 9,250 shares of Celgene Corporation stock. The stock was sold at an average price of $125.59, for a total value of $1,161,707.50.

Celgene Corporation (CELG) opened at 134.87 on Tuesday. The firm has a market cap of $105.31 billion, a price-to-earnings ratio of 50.65 and a beta of 1.89. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $136.12. The firm has a 50-day moving average price of $121.46 and a 200 day moving average price of $120.59.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.47 by $0.21. Celgene Corporation had a return on equity of 70.94% and a net margin of 18.32%. The business had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3.04 billion. During the same quarter last year, the business posted $1.32 earnings per share. The company’s revenue for the quarter was up 17.8% on a year-over-year basis. Equities analysts predict that Celgene Corporation will post $7.28 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was posted by Stock Observer and is owned by of Stock Observer. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.thestockobserver.com/2017/07/18/celgene-corporation-celg-director-sells-1230712-50-in-stock-updated-updated.html.

Several equities analysts have weighed in on the company. Leerink Swann reaffirmed a “market perform” rating on shares of Celgene Corporation in a research note on Monday, March 20th. Cann reissued a “buy” rating and issued a $148.00 price target on shares of Celgene Corporation in a research note on Tuesday, April 4th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $148.00 price target on shares of Celgene Corporation in a research note on Wednesday, April 5th. Jefferies Group LLC reissued a “buy” rating and issued a $154.00 price target on shares of Celgene Corporation in a research note on Tuesday, April 11th. Finally, Robert W. Baird reissued an “outperform” rating and issued a $162.00 price target on shares of Celgene Corporation in a research note on Wednesday, April 19th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twenty-two have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $141.00.

Several hedge funds and other institutional investors have recently made changes to their positions in CELG. Hudson Valley Investment Advisors Inc. ADV boosted its position in shares of Celgene Corporation by 10.6% in the second quarter. Hudson Valley Investment Advisors Inc. ADV now owns 22,861 shares of the biopharmaceutical company’s stock worth $2,969,000 after buying an additional 2,185 shares during the period. CWM LLC boosted its position in shares of Celgene Corporation by 9.3% in the second quarter. CWM LLC now owns 44,467 shares of the biopharmaceutical company’s stock worth $5,775,000 after buying an additional 3,773 shares during the period. TNB Financial acquired a new stake in Celgene Corporation during the second quarter valued at about $4,873,000. V Wealth Management LLC boosted its stake in Celgene Corporation by 62.2% in the second quarter. V Wealth Management LLC now owns 16,344 shares of the biopharmaceutical company’s stock valued at $2,113,000 after buying an additional 6,265 shares during the last quarter. Finally, Regent Investment Management LLC boosted its stake in Celgene Corporation by 15.7% in the second quarter. Regent Investment Management LLC now owns 52,284 shares of the biopharmaceutical company’s stock valued at $6,790,000 after buying an additional 7,095 shares during the last quarter. 78.16% of the stock is currently owned by hedge funds and other institutional investors.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Insider Buying and Selling by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply